Skip to main content
Eli LillyInvestment

Stipple Bio Announces Multi-Target Multi-Modality Oncology Research Collaboration with Lilly

Source: Autobound Signal API · 114 signals tracked for Eli Lilly · updated

Get Eli Lilly's live signals in Claude or ChatGPT, or by API

AskWhat changed at Eli Lilly this week? Use Autobound signals for lilly.com.

What happened

Eli Lilly is making an equity investment in Stipple Bio as part of their strategic collaboration agreement.

Source

Article excerpt

– Strategic research collaboration leverages Stipple Bio's innovative Pointillist Platform to identify tumor-specific cell surface epitope binders and Lilly’s proprietary oncology technologies – CAMBRIDGE, Mass., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Stipple Bio, Inc., a private biotechnology company harnessing epitope-level precision to create targeted cancer therapies, today announced that it has entered into a multi-target multi-modality strategic research collaboration and license agreement with Eli Lilly and Company (“Lilly”). Stipple Bio will leverage its innovative Pointillist Platform and extensive research experience to discover novel tumor-specific cell surface epitope binders, which Lilly will combine with its proprietary oncology technologies to advance high therapeutic index compounds across multiple modalities. Stipple Bio's Pointillist Platform identifies novel tumor-specific cell surface epitope binders to enable the development of high therapeutic index oncology therapies that selectively target tumor cells, with the potential to increase efficacy and reduce on-target, off-tumor toxicity. “Stipple Bio was founded with the belief that epitope-level precision could distinguish tumor cells from healthy tissue, unlocking a new generation of effective and safer cancer therapies directed at targets whose expression on healthy cells has historically limited their...

Keep reading with a free account

The rest of this article, and every signal for Eli Lilly, is in your free account.

Extracted from this sentence

Under the terms of the agreement, Stipple Bio will receive an upfront payment and an equity investment in Stipple Bio.

Extracted by Autobound

From the Signal API record
Event
Investment

What this signalsAn investment often shows where the company plans to grow.

Takes effect
Nov 16, 2026
Location
Cambridge, Massachusetts, United States
Financing type
Equity

Companies

  • Stipple Bio, Inc.Related companystipple.bio

More investment signals at other companies

The full record

From the Signal API record

Extraction

Confidence
90%
Detected
Nov 16, 2026
signal_type
news
signal_subtype
invests_into

Use this data

Get every investment signal for Eli Lilly and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Eli Lilly this week?”

  2. Send it to your own tools

    The Signal API returns investment signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/202e5bcf-d328-6191-2584-890d4fb889c5 returns this record as JSON. POST /v1/companies/enrich returns every signal for lilly.com.

{
  "signal_id": "202e5bcf-d328-6191-2584-890d4fb889c5",
  "signal_type": "news",
  "signal_subtype": "invests_into",
  "detected_at": "2026-11-16T21:00:00+00:00",
  "company": {
    "name": "Eli Lilly",
    "domain": "lilly.com"
  },
  "data": {
    "url": "https://www.globenewswire.com/news-release/2026/11/16/3404075/0/en/stipple-bio-announces-multi-target-multi-modality-oncology-research-collaboration-with-lilly.html",
    "title": "Stipple Bio Announces Multi-Target Multi-Modality Oncology Research Collaboration with Lilly",
    "excerpt": "– Strategic research collaboration leverages Stipple Bio's innovative Pointillist Platform to identify tumor-specific cell surface epitope binders and Lilly’s proprietary oncology technologies – CAMBRIDGE, Mass., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Stipple Bio, Inc., a private biotechnology company harnessing epitope-level precision to create targeted cancer therapies, today announced that it has entered into a multi-target multi-modality strategic research collaboration and license agreement with Eli Lilly and Company (“Lilly”). Stipple Bio will leverage its innovative Pointillist Platform and extensive research experience to discover novel tumor-specific cell surface epitope binders, which Lilly will combine with its proprietary oncology technologies to advance high therapeutic index compounds across multiple modalities. Stipple Bio's Pointillist Platform identifies novel tumor-specific cell surface epitope binders to enable the development of high therapeutic index oncology therapies that selectively target tumor cells, with the potential to increase efficacy and reduce on-target, off-tumor toxicity. “Stipple Bio was founded with the belief that epitope-level precision could distinguish tumor cells from healthy tissue, unlocking a new generation of effective and safer cancer therapies directed at targets whose expression on healthy cells has historically limited their...",
    "summary": "Eli Lilly is making an equity investment in Stipple Bio as part of their strategic collaboration agreement.",
    "location": "Cambridge, Massachusetts, United States",
    "planning": false,
    "image_url": "https://ml.globenewswire.com/Resource/Download/96c458bd-cad2-4343-89d4-8c60bcfde0a5",
    "confidence": 0.9,
    "published_at": "2026-11-16T21:00:00Z",
    "location_data": [
      {
        "city": "Cambridge",
        "state": "Massachusetts",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-11-16",
    "article_sentence": "Under the terms of the agreement, Stipple Bio will receive an upfront payment and an equity investment in Stipple Bio.",
    "financing_type_tags": [
      "equity"
    ],
    "related_company_name": "Stipple Bio, Inc.",
    "related_company_domain": "stipple.bio"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.